Skin cancer vaccine BLA submitted by...?
Odds right now: June 30, 2027? 89%, March 31, 2027 75%.
Cleus is reading the rules and searching the web and X…
Usually 15–40 seconds.
Cleus’s own estimate from public information. Not financial advice.
A fresh, deeper run: Cleus searches wider, thinks it through, and lays out the bull and bear case, the scenarios and the one thing that would change its mind.
Which side the winners are on
The top holders of “June 30, 2027?”, weighted by what each wallet has made on Polymarket all-time. 16 of them have made $25K+.
When proven winners lean against the price, it’s worth a second look. When they agree with it, the price is probably fair.
Big bets in this market that stand out
Orders of $500+ from the last 30 days, scored for new wallets, first markets, long odds and size. Evidence, not accusations — and never a name.
Nothing unusual in the last few hours — big bets are coming from established wallets at normal odds.
How it actually resolves
The written rules below decide this market — not the headline.
Rules risk: Resolves on "credible reporting", which leaves room to argue.
Full rules from Polymarket
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program. A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication. A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof. The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify. If the FDA grants approval of intismeran autogene on or before June 30, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed. The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.
Ask Cleus about this market
Cleus has this market’s prices, rules, its own odds and the unusual bets in front of it, and searches the web and X for the rest.
Analysis, not financial advice. Prediction markets can lose you money. Free: 3 questions a day.
More tech & ai markets
Questions
What are the odds of Skin cancer vaccine BLA submitted by...?
On Polymarket, June 30, 2027? is trading at 89%. Other outcomes: June 30, 2027? 89%, March 31, 2027 75%. Prices update live.
When does this market end?
It is scheduled to end on July 1, 2027, then settles once the result is confirmed under its rules.
What does Cleus predict?
Cleus has not made a call on this market yet.
Prices from Polymarket’s public data, refreshed every few minutes. Cleus odds are Cleus’s own estimate. Unusual-bet scores are statistical patterns, not findings of wrongdoing. Not financial advice; not affiliated with Polymarket.